Skip to main content
. 2022 Nov 30;9:1059111. doi: 10.3389/fcvm.2022.1059111

TABLE 1.

Comparison of the clinical characteristics between patients with (LAAT+) and without LAAT (LAAT).

Variable LAAT- (n = 2,859) LAAT+ (n = 250) p a
Demographics
Age (years) 67 [59–73] 72 [64–78] <0.001
AF/AFL type
AF/AFL paroxysmal 1,247 (44%) 33 (13%) <0.001
AF/AFL persistent 1,365 (48%) 183 (73%) <0.001
AF/AFL long-standing persistent 237 (8%) 34 (14%) 0.007
AF chronic 109 (4%) 20 (8%) 0.004
Comorbidities
Heart failure 1,165 (41%) 171 (69%) <0.001
Heart failure with reduced LVEF 380 (13%) 96 (39%) <0.001
Hypertension 2,171 (76%) 195 (79%) 0.393
Diabetes mellitus 683 (24%) 91 (37%) <0.001
Previous stroke 206 (7.2%) 29 (12%) 0.017
TIA 75 (3%) 15 (6%) 0.005
Previous ischemic stroke/TIA/systemic embolism 278 (9.7%) 35 (14%) 0.040
Previous hemorrhagic stroke 14 (0.5%) 3 (1.2%) 0.148
Vascular disease 949 (33%) 118 (47%) <0.001
Myocardial infarction 372 (13%) 59 (28%) <0.001
Coronary artery disease 811 (29%) 94 (38%) 0.002
Peripheral artery disease 149 (5%) 26 (10%) <0.001
Moderate to severe mitral stenosis 12 (0.4%) 5 (2%) 0.009
Moderate to severe mitral regurgitation 442 (15%) 81 (32%) <0.001
Moderate to severe aortic stenosis 47 (1.6%) 15 (6%) <0.001
CIED 341 (12%) 57 (23%) <0.001
eGFR < 50 (mL/min) 82 [64–103] 74 [51–93] <0.001
Previous bleeding 114 (4.0%) 17 (6.9%) 0.05
Anemia 431 (16%) 53 (23%) <0.01
Labile INR 50 (2%) 23 (9%) <0.001
Smoking 902 (33%) 109 (46%) <0.001
Alcohol 106 (4%) 23 (9%) <0.001
Thromboembolic risk and indications to chronic OAC
CHA2DS2-VASc score 3 [2–4] 4 [3–5] 0.010
Antithrombotic therapy
Chronic OAC therapy 2,553 (89%) 200 (80%) <0.001

ap-value refers for the differences between LAAT (+) and LAAT (-) groups.

AF, atrial fibrillation; AFL, atrial fibrillation; CIED, cardiac implanted electrical device; eGFR, estimated glomerular filtration rate; INR, international normalized ratio; LAAT, left atrial appendage thrombus; MS, mitral stenosis; OAC, an oral anticoagulant. TIA, transient ischemic attack.